EBMT 2023 | Phase I study of donor-derived γδ T cells as relapse prophylaxis post haplo/cy
Joseph McGuirk, DO, The University of Kansas Medical Center, Kansas City, KS, discusses the rationale and findings of a Phase I study evaluating donor-derived expanded and activated gamma delta (γδ) T cells as relapse prophylaxis post-haploidentical transplantation and cyclophosphamide (haplo/cy). The study treated seven patients to date and has reported no relapses and only low-grade graft-versus-host disease (GvHD). This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Envision, Kite, AlloVir, BMS, Novartis, CRISPR, Nektar, Caribou Bio, Sana Technologies, Legend Biotech
